Aristotle University of Thessaloniki, Thessaloniki, Greece
Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK.
BMJ Open Ophthalmol. 2024 Feb 10;9(1):e001516. doi: 10.1136/bmjophth-2023-001516.
Age-related macular degeneration is a major cause of blindness, and the development of anti-vascular endothelial growth factor (VEGF) intravitreal treatments has revolutionised the management of the disease. At the same time, new challenges and unmet needs arose due to the limitations of the current therapeutic options. Neovascularisation development during the course of the disease has a complex pathogenetic mechanism, and several biomarkers and their association with treatment outcomes have been investigated. We reviewed the relevant literature about neovascularisation development and biomarkers related to response to treatment. Improving our knowledge on the field can improve patient outcomes and offer personalised care.
年龄相关性黄斑变性是导致失明的主要原因之一，抗血管内皮生长因子（VEGF）眼内治疗的发展彻底改变了疾病的治疗方式。与此同时，由于目前治疗方案的局限性，出现了新的挑战和未满足的需求。疾病过程中新生血管的发展具有复杂的发病机制，已经研究了几种生物标志物及其与治疗结果的关系。我们回顾了有关新生血管发展和与治疗反应相关的生物标志物的相关文献。提高我们在这一领域的认识可以改善患者的预后并提供个性化的护理。
